Home | | Modern Pharmacology with Clinical Applications | Capsofungin Antifungal Drug

Chapter: Modern Pharmacology with Clinical Applications: Antifungal Drugs

Capsofungin Antifungal Drug

Capsofungin (Cancidas) is a semisynthetic lipopeptide known as an echinocandin, the first representative of a new class of antifungal agents that inhibit the synthesis of -(1,3)-D-glucan, a cell wall component of filamentous fungi.

CAPSOFUNGIN

 

Capsofungin (Cancidas) is a semisynthetic lipopeptide known as an echinocandin, the first representative of a new class of antifungal agents that inhibit the synthesis of -(1,3)-D-glucan, a cell wall component of filamentous fungi. Capsofungin has in vitro activity against Asper-gillus fumigatus, Aspergillus flavus, and Aspergillus ter-reus; it is approved for the treatment of invasive as-pergillosis in patients not responding to other antifungal agents, such as amphotericin B, lipid formulations of am-photericin B, and itraconazole. Additional indications for the use of this drug await further clinical study.

 

Capsofungin is not absorbed from the gastrointesti-nal tract. It is highly protein bound and has a serum half-life of 9 to 11 hours. Capsofungin appears to un-dergo liver metabolism and is not excreted in the urine. Adverse effects are mediated through histamine re-lease; they include facial flushing, rash, fever, and pruri-tis. Nausea and vomiting have also been reported. Dose reductions are required in the presence of moderate hepatic insufficiency.

 

 

Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Modern Pharmacology with Clinical Applications: Antifungal Drugs : Capsofungin Antifungal Drug |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.